Acral lentiginous melanoma: Who benefits from sentinel lymph node biopsy?

Ito, Takamichi; Wada, Maiko; Nagae, Konosuke; Nakano-Nakamura, Misa; Nakahara, Takeshi; Hagihara, Akihito; Furue, Masutaka; Uchi, Hiroshi

doi:10.1016/j.jaad.2014.10.008

Cited by 50 publications

(50 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the benefits of SLNB for predicting the prognosis of cutaneous melanoma have been proven in several reports , the prognostic value of this procedure for patients with AM has been poorly evaluated. Two studies of patients with acral lentiginous melanoma, which is a subtype of AM, have demonstrated that patients with a positive SLN have significantly worse prognosis compared to those with a negative SLN, supporting our findings. It can be assumed that SLN status is a significant prognostic factor for both local control and survival in the patients with thick AM.…”

Section: Discussionsupporting

confidence: 89%

Surgical excision margin for primary acral melanoma

Lee

Kim

Lee

et al. 2016

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 89%

Surgical excision margin for primary acral melanoma

Lee

Kim

Lee

et al. 2016

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…We previously reported the efficacy of sentinel lymph node (SLN) biopsy in patients with ALM and the clinicopathological condition that SLN biopsy should be performed . Our previous results well fitted with the current recommendations of the American Joint Committee of Cancer and the National Comprehensive Cancer Network.…”

Section: Introductionsupporting

confidence: 76%

Acral lentiginous melanoma versus other melanoma: A single‐center analysis in Japan

Wada

Ito

Tsuji

et al. 2017

The Journal of Dermatology

Self Cite

View full text Add to dashboard Cite

We summarize herein our 14-year experience of conventional treatment outcomes before the era of moleculartargeted therapy and immunotherapy. Specifically, we conducted a retrospective review of our 252 patients with primary cutaneous melanoma (acral lentiginous melanoma [ALM], n = 121; non-acral lentiginous melanoma [non-ALM], n = 131), and compared the prognostic factors between ALM and non-ALM. Melanoma-specific survival and disease-free survival were estimated using the Kaplan-Meier method. Regarding the results, all patients were Japanese (106 male and 146 female), with a mean age of 60.1 years. Among ALM patients, age was elder and primary tumor size was larger than non-ALM. As for tumor thickness, in situ lesions were more frequently observed in ALM. There was no significant difference in the distribution of tumor thickness between the two groups when excluding the in situ lesions. For treatment of the primary melanoma, 248 patients (98.4%) had undergone curative surgical excision and 120 patients with more than 1 mm or ulcerated melanoma had undergone sentinel lymph node biopsy. Patients with systemic metastasis primarily underwent dacarbazine-based chemotherapy. The Kaplan-Meier survival curves revealed no significant difference in melanoma-specific survival and disease-free survival between those with ALM and non-ALM. The results also showed that both ALM and non-ALM, when they initially metastasize, first affect the regional lymph nodes. Incisional biopsy was not an adverse prognostic factor. These results suggest that ALM does not differ in its biological behavior from non-ALM, so we can consider ALM as being equivalent to non-ALM. The initial treatment for ALM and non-ALM can involve the same strategy.

show abstract

“…Another interesting finding of our study is that the >2‐mm‐thick melanomas expressed a significantly higher level of FoxM1 compared to the ≤2‐mm‐thick melanomas; the in‐situ melanomas rarely expressed FoxM1 (Figure ). We observed that FoxM1 expression was correlated strongly with Breslow thickness, a well‐known risk factor in melanoma . We also observed that the tumour cells at the nest periphery express FoxM1 more often compared to the tumour cells at the nest centre (data not shown).…”

Section: Discussionmentioning

confidence: 60%